Ipca Laboratories
- Advice
- Hold
Ipca Laboratories Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Ipca Laboratories
Start SIPIpca Laboratories Investment Rating
-
Master Rating:
-
Ipca Laboratories has an operating revenue of Rs. 6,021.79 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 19% is great, ROE of 16% is good. The company has a reasonable debt to equity of 7%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 34 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 80 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|
| Oper Rev Qtr Cr | 1,433 | 1,485 | 1,469 | 1,168 |
| Operating Expenses Qtr Cr | 1,219 | 1,213 | 1,212 | 989 |
| Operating Profit Qtr Cr | 214 | 272 | 257 | 179 |
| Depreciation Qtr Cr | 57 | 55 | 53 | 52 |
| Interest Qtr Cr | 10 | 9 | 7 | 3 |
| Tax Qtr Cr | 52 | 77 | 72 | 27 |
| Net Profit Qtr Cr | 120 | 168 | 144 | 110 |
Ipca Laboratories Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 16
- 20 Day
- 795.34
- 50 Day
- 820.13
- 100 Day
- 845.3
- 200 Day
- 883.12
- 20 Day
- 792.92
- 50 Day
- 830.31
- 100 Day
- 848.76
- 200 Day
- 884.98
Ipca Laboratories Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 790.77 |
| Second Resistance | 797.14 |
| Third Resistance | 802.82 |
| RSI | 33.99 |
| MFI | 24.63 |
| MACD Single Line | -15.55 |
| MACD | -14.4 |
| Support | |
|---|---|
| First Resistance | 778.72 |
| Second Resistance | 773.04 |
| Third Resistance | 766.67 |
Ipca Laboratories Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 67,689 | 2,106,482 | 31.12 |
| Week | 121,823 | 6,423,727 | 52.73 |
| 1 Month | 268,393 | 16,001,576 | 59.62 |
| 6 Month | 289,307 | 14,829,877 | 51.26 |
Ipca Laboratories Result Highlights
Ipca Laboratories Synopsis
NSE-Medical-Generic Drugs
Ipca Laboratorie is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 5399.36 Cr. and Equity Capital is Rs. 25.37 Cr. for the Year ended 31/03/2022. Ipca Laboratories Ltd. is a Public Limited Listed company incorporated on 19/10/1949 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1949PLC007837 and registration number is 007837.| Market Cap | 19,826 |
| Sales | 5,555 |
| Shares in Float | 13.70 |
| No of funds | 245 |
| Yield | 0.51 |
| Book Value | 3.59 |
| U/D Vol ratio | 0.5 |
| LTDebt / Equity | 7 |
| Alpha | -0.09 |
| Beta | 0.36 |
Ipca Laboratories
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 46.29% | 46.29% | 46.29% | |
| Mutual Funds | 29.79% | 29.71% | 29.41% | |
| Insurance Companies | 3.76% | 3.57% | 3.9% | |
| Foreign Portfolio Investors | 10.46% | 10.57% | 10.61% | |
| Financial Institutions/ Banks | ||||
| Individual Investors | 7.41% | 7.44% | 7.5% | |
| Others | 2.29% | 2.42% | 2.29% |
Ipca Laboratories Management
| Name | Designation |
|---|---|
| Mr. Premchand Godha | Chairman & M.D & CEO |
| Mr. Ajit Kumar Jain | Joint Managing Director & CFO |
| Mr. Pranay Godha | Executive Director |
| Mr. Prashant Godha | Executive Director |
| Mr. Anand T Kusre | Independent Director |
| Mr. Dev Parkash Yadava | Independent Director |
| Dr.(Mrs.) Manisha Premnath | Independent Director |
| Mr. Kamal Kishore Seth | Independent Director |
Ipca Laboratories Forecast
Price Estimates
Ipca Laboratories FAQs
What is Share Price of Ipca Laboratories ?
Ipca Laboratories share price is ₹780 As on 26 March, 2023 | 19:54
What is the Market Cap of Ipca Laboratories ?
The Market Cap of Ipca Laboratories is ₹19788.9 Cr As on 26 March, 2023 | 19:54
What is the P/E ratio of Ipca Laboratories ?
The P/E ratio of Ipca Laboratories is 37.7 As on 26 March, 2023 | 19:54
What is the PB ratio of Ipca Laboratories ?
The PB ratio of Ipca Laboratories is 3.6 As on 26 March, 2023 | 19:54